Bavarian Nordic A/S (CPH:BAVA)(FRA:BV3), a fully integrated biotechnology company, announced on Friday the signing of a new alliance with the US Department of Defence (DoD) for the development of a prophylactic vaccine against the equine encephalitis virus, a rare, but potentially deadly mosquito-borne illness.
With funding from the DoD, Bavarian Nordic will utilise its proprietary MVA-BN platform to develop a vaccine against various strains of the virus, for which there is currently no preventative vaccine treatment available. This agreement includes total potential considerations of approximately USD36m.
An MVA-BN based candidate vaccine targeting three separate equine encephalitis viruses including Eastern (EEEV), Venezuelan (VEEV) and Western (WEEV), has already demonstrated efficacy against all three viruses in preclinical models, the company added.
This multi-year collaboration will include further preclinical studies to support clinical development, GMP production and establishment of safety and immunogenicity in humans. Also, clinical proof of concept data will warrant further development of the MVA-BN based candidate vaccine with potential follow-on funding towards FDA licensure and production. This vaccine would then be available to the DoD as needed to vaccinate individuals who may be deployed in a region considered at high risk for a particular illness.
The award of this multi-year contract does not change the financial guidance for 2018, the company added.
Bavarian Nordic is focused on the development of innovative and safe therapies against cancer and infectious diseases.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer